Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Lung Cancer
Vicus Therapeutics Records Last Patient Visit of Phase 2, VT-122 Trial for the Treatment of Cachexia in Patients With Advanced Lung Cancer
May 13th, 2008
Vicus Therapeutics, LLC, a biopharmaceutical company focused on oncology supportive care, announced the completion of the last patient visit in its study VT1-CAX-001, a Phase 2 trial of VT-122. The compound was tested for the treatment of cachexia in weight losing subjects with Stage IV, non-small cell lung cancer (NSCLC). The Phase 2 clinical trial was conducted in India and the final study report is expected in June 2008. A total of 59 subjects were deemed eligible for this multi-center, randomized, open-label controlled Phase 2 study in weight losing Stage IV NSCLC patients not on chemotherapy. The 12 subjects randomized to the control arm received best supportive...
Source: Cancer Weekly (2008-05-13)
|
